Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics

Authors: Annie N. Cowell, Eva S. Istvan, Amanda K. Lukens, Marı́a G. Gómez-Lorenzo, Manu Vanaerschot, Tomoyo Sakata‐Kato, Erika L. Flannery, Pamela Magistrado, Edward Owen, Matthew Abraham, Gregory LaMonte, Heather J. Painter, Roy M. Williams, Virginia Franco, María Linares, Ignacio Arriaga, Selina Bopp, Victoria Corey, Nina F. Gnädig, Olivia Coburn‐Flynn, Christin Reimer, Purva Gupta, James M. Murithi, Pedro A. Moura, Olivia Fuchs, Erika Sasaki, Sang Woon Kim, Christine Teng, Lawrence Wang, Aslı Akidil, Sophie Adjalley, Paul Willis, Dionicio Siegel, Olga Tanaseichuk, Zhong Yang, Yingyao Zhou, Manuel Llinás, Sabine Ottilie, Francisco‐Javier Gamo, Lee M, Daniel E. Goldberg, David A. Fidock, Dyann F. Wirth, Elizabeth A. Winzeler - Science 2018 cited by 273

Dissecting Plasmodium drug resistance Malaria is a deadly disease with no effective vaccine. Physicians thus depend on antimalarial drugs to save lives, but such compounds are often rendered ineffective when parasites evolve resistance. Cowell et al. systematically studied patterns of Plasmodium falciparum genome evolution by analyzing the sequences of clones that were resistant to diverse antimalarial compounds across the P. falciparum life cycle (see the Perspective by Carlton). The findings identify hitherto unrecognized drug targets and drug-resistance genes, as well as additional alleles in known drug-resistance genes. Science , this issue p. 191 ; see also p. 159